Approved comparison material connected to this topic.
4 total recordsSource comparisons are presented without a generated winner.
Tesamorelin vs CJC-1295: FDA GHRH vs Research Tesamorelin vs CJC-1295: FDA GHRH (-18% visceral fat, Phase III) vs research peptide (2-10x GH, Phase I). Cost, dosing, and who picks which. Tesamorelin (Egrifta S…
FDA Approval Status Not approved. Classified as investigational research peptide Approved for pediatric growth hormone deficiency, adult GH deficiency, AIDS-related wasting, and other specific indications Appr…
Cost is a significant factor, and the range spans two orders of magnitude depending on the source. Egrifta SV (brand tesamorelin) ~$3,085/month Prescription required; insurance may cover for HIV indication Com…
The evidence gap between tesamorelin and CJC-1295 is the single most important factor in this comparison.